Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ARWR NYSE:BHC NASDAQ:NAMS NASDAQ:URGN On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeARWRArrowhead Pharmaceuticals$29.08+3.9%$18.52$9.57▼$29.34$4.02B12.02 million shs2.70 million shsBHCBausch Health Cos$7.35+1.9%$6.82$4.25▼$9.85$2.72B0.482.67 million shs1.01 million shsNAMSNewAmsterdam Pharma$27.00+5.2%$22.81$14.06▼$27.29$3.04B-0.01874,401 shs1.54 million shsURGNUrogen Pharma$18.88+0.4%$17.43$3.42▼$21.01$873.39M1.11.53 million shs1.03 million shsA Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for September 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceARWRArrowhead Pharmaceuticals+0.72%+25.34%+70.01%+66.57%+16.76%BHCBausch Health Cos-2.04%+0.70%+21.06%+51.89%+16.00%NAMSNewAmsterdam Pharma+3.14%+7.14%+18.09%+27.41%+60.17%URGNUrogen Pharma-2.94%-2.29%-9.27%+155.09%+34.57%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeARWRArrowhead Pharmaceuticals$29.08+3.9%$18.52$9.57▼$29.34$4.02B12.02 million shs2.70 million shsBHCBausch Health Cos$7.35+1.9%$6.82$4.25▼$9.85$2.72B0.482.67 million shs1.01 million shsNAMSNewAmsterdam Pharma$27.00+5.2%$22.81$14.06▼$27.29$3.04B-0.01874,401 shs1.54 million shsURGNUrogen Pharma$18.88+0.4%$17.43$3.42▼$21.01$873.39M1.11.53 million shs1.03 million shsA Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for September 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceARWRArrowhead Pharmaceuticals+0.72%+25.34%+70.01%+66.57%+16.76%BHCBausch Health Cos-2.04%+0.70%+21.06%+51.89%+16.00%NAMSNewAmsterdam Pharma+3.14%+7.14%+18.09%+27.41%+60.17%URGNUrogen Pharma-2.94%-2.29%-9.27%+155.09%+34.57%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceARWRArrowhead Pharmaceuticals 3.00Buy$43.1448.36% UpsideBHCBausch Health Cos 2.00Hold$9.0022.53% UpsideNAMSNewAmsterdam Pharma 2.90Moderate Buy$41.5553.87% UpsideURGNUrogen Pharma 3.00Buy$32.0069.49% UpsideCurrent Analyst Ratings BreakdownLatest URGN, ARWR, BHC, and NAMS Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails9/2/2025ARWRArrowhead PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$80.008/25/2025NAMSNewAmsterdam PharmaWells Fargo & CompanySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOverweight$45.008/18/2025URGNUrogen PharmaPiper SandlerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOverweight$36.008/11/2025ARWRArrowhead PharmaceuticalsB. RileySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong-Buy8/11/2025ARWRArrowhead PharmaceuticalsChardan CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$60.008/11/2025URGNUrogen PharmaHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$50.00 ➝ $40.008/8/2025ARWRArrowhead PharmaceuticalsRoyal Bank Of CanadaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOutperform$40.00 ➝ $38.008/7/2025NAMSNewAmsterdam PharmaRoyal Bank Of CanadaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOutperform$38.00 ➝ $39.008/5/2025URGNUrogen PharmaD. Boral CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$25.007/28/2025ARWRArrowhead PharmaceuticalsTD CowenSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong-Buy7/17/2025NAMSNewAmsterdam PharmaThe Goldman Sachs GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageNeutral$27.00(Data available from 9/5/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookARWRArrowhead Pharmaceuticals$3.55M1,132.56N/AN/A$1.54 per share18.88BHCBausch Health Cos$9.63B0.28$7.73 per share0.95($0.89) per share-8.25NAMSNewAmsterdam Pharma$45.56M66.75N/AN/A$8.20 per share3.29URGNUrogen Pharma$90.40M9.66N/AN/A($0.21) per share-89.90Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateARWRArrowhead Pharmaceuticals-$599.49M-$1.28N/AN/AN/AN/A-40.91%-11.62%N/ABHCBausch Health Cos-$46M$0.2628.251.58N/A0.99%-852.36%5.25%10/29/2025 (Estimated)NAMSNewAmsterdam Pharma-$241.60M-$1.62N/AN/AN/A-259.07%-27.27%-25.00%11/5/2025 (Estimated)URGNUrogen Pharma-$126.87M-$3.32N/AN/AN/A-164.44%-97,487.15%-59.38%11/5/2025 (Estimated)Latest URGN, ARWR, BHC, and NAMS EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/7/2025Q3 2025ARWRArrowhead Pharmaceuticals-$0.94-$1.26-$0.32-$1.26$29.01 million$27.77 million8/7/2025Q2 2025URGNUrogen Pharma-$0.82-$1.05-$0.23-$1.05$23.06 million$24.22 million8/6/2025Q2 2025NAMSNewAmsterdam Pharma-$0.52-$0.15+$0.37-$0.15$1.44 million$19.15 million7/30/2025Q2 2025BHCBausch Health Cos$0.97$0.90-$0.07$0.40$2.47 billion$2.57 billionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthARWRArrowhead PharmaceuticalsN/AN/AN/AN/AN/ABHCBausch Health CosN/AN/AN/AN/AN/ANAMSNewAmsterdam PharmaN/AN/AN/AN/AN/AURGNUrogen PharmaN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioARWRArrowhead Pharmaceuticals0.394.874.87BHCBausch Health Cos141.901.310.98NAMSNewAmsterdam PharmaN/A21.0821.08URGNUrogen PharmaN/A4.143.99Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipARWRArrowhead Pharmaceuticals62.61%BHCBausch Health Cos78.65%NAMSNewAmsterdam Pharma89.89%URGNUrogen Pharma91.29%Insider OwnershipCompanyInsider OwnershipARWRArrowhead Pharmaceuticals4.30%BHCBausch Health Cos19.97%NAMSNewAmsterdam Pharma20.84%URGNUrogen Pharma4.70%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableARWRArrowhead Pharmaceuticals400138.26 million132.31 millionOptionableBHCBausch Health Cos20,700370.13 million296.21 millionOptionableNAMSNewAmsterdam Pharma4112.63 million89.16 millionOptionableURGNUrogen Pharma20046.26 million44.09 millionOptionableURGN, ARWR, BHC, and NAMS HeadlinesRecent News About These CompaniesVestal Point Capital LP Boosts Position in Urogen Pharma $URGNSeptember 4 at 7:17 AM | marketbeat.comRA Capital Management L.P. Acquires Shares of 3,206,271 Urogen Pharma $URGNSeptember 4 at 7:02 AM | marketbeat.comNuveen LLC Invests $1.03 Million in Urogen Pharma $URGNSeptember 3 at 3:38 AM | marketbeat.comPartners Capital Investment Group LLP Invests $170,000 in Urogen Pharma $URGNAugust 24, 2025 | marketbeat.comUroGen Pharma to Present at Upcoming Investor ConferencesAugust 21, 2025 | globenewswire.comFox Run Management L.L.C. Takes Position in Urogen Pharma $URGNAugust 21, 2025 | marketbeat.comPiper Sandler Initiates Coverage of UroGen Pharma (URGN) with Overweight RecommendationAugust 20, 2025 | msn.comPiper starts ‘underestimated’ UroGen Pharma with an OverweightAugust 19, 2025 | msn.comUroGen Pharma initiated with an Overweight at Piper SandlerAugust 18, 2025 | msn.comUroGen Pharma: Targeting Profits In 2027August 18, 2025 | seekingalpha.comOak Ridge Investments LLC Has $815,000 Position in Urogen Pharma (NASDAQ:URGN)August 17, 2025 | marketbeat.comQ3 EPS Estimates for Urogen Pharma Reduced by HC WainwrightAugust 16, 2025 | marketbeat.comUrogen Pharma (NASDAQ:URGN) Insider Mark Schoenberg Sells 10,000 SharesAugust 15, 2025 | marketbeat.comUrogen Pharma (NASDAQ:URGN) Receives Consensus Recommendation of "Buy" from BrokeragesAugust 14, 2025 | marketbeat.com17,571 Shares in Urogen Pharma (NASDAQ:URGN) Acquired by Persistent Asset Partners LtdAugust 13, 2025 | marketbeat.comUroGen Pharma’s Earnings Call: Achievements and ChallengesAugust 13, 2025 | msn.comUroGen Pharma Ltd. (NASDAQ:URGN) Q2 2025 Earnings Call TranscriptAugust 12, 2025 | msn.comHC Wainwright Issues Pessimistic Forecast for Urogen Pharma (NASDAQ:URGN) Stock PriceAugust 12, 2025 | marketbeat.comUrogen Pharma (NASDAQ:URGN) Releases Earnings Results, Misses Expectations By $0.20 EPSAugust 11, 2025 | marketbeat.comUroGen Pharma Ltd. (NASDAQ:URGN) Just Released Its Second-Quarter Results And Analysts Are Updating Their EstimatesAugust 10, 2025 | finance.yahoo.comUroGen Pharma Ltd. (URGN) Q2 2025 Earnings Call TranscriptAugust 9, 2025 | seekingalpha.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeURGN, ARWR, BHC, and NAMS Company DescriptionsArrowhead Pharmaceuticals NASDAQ:ARWR$29.08 +1.08 (+3.86%) Closing price 04:00 PM EasternExtended Trading$28.95 -0.13 (-0.45%) As of 05:37 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes Plozasiran, which is in Phase 2b and one Phase 3 clinical trial to treat hypertriglyceridemia, mixed dyslipidemia, and chylomicronemia syndrome; Zodasiran that is in Phase 2b clinical trial for the treatment of dyslipidemia and hypertriglyceridemia; ARO-PNPLA3, which is in Phase 1 clinical trial to treat patients with non-alcoholic steatohepatitis; ARO-RAGE that is in Phase 1/2a clinical trial to treat inflammatory pulmonary conditions; and ARO-MUC5AC, which is in Phase 1/2a clinical trial to treat muco-obstructive pulmonary diseases. It also develops ARO-MMP7 that is in Phase 1/2a clinical trial for treatment of idiopathic pulmonary fibrosis; ARO-DUX4 for the treatment of facioscapulohumeral muscular dystrophy; ARO-SOD1 for the potential treatment of amyotrophic lateral sclerosis; and ARO-C3, which is in Phase 1/2a clinical trial for the treatment of patients with various complement mediated or complement associated renal diseases. In addition, the company is involved in the development of JNJ-3989, which is in Phase 2 clinical trial to treat chronic hepatitis B virus infection; Olpasiran that is in Phase 3 clinical trial to reduce the production of apolipoprotein A; GSK-4532990 that is in phase 2 clinical trial to treat liver diseases; HZN-457, which is in phase 1 clinical trial to treat uncontrolled gout; and Fazirsiran that is in Phase 3 clinical trial for the treatment for liver disease associated with alpha-1 antitrypsin deficiency. Arrowhead Pharmaceuticals, Inc. has license and research collaboration agreements with Janssen Pharmaceuticals, Inc.; Takeda Pharmaceutical Company Limited; Horizon Therapeutics Ireland DAC; Amgen Inc.; and Glaxosmithkline Intellectual Property (No. 3) Limited. The company was founded in 2003 and is headquartered in Pasadena, California.Bausch Health Cos NYSE:BHC$7.34 +0.14 (+1.87%) Closing price 03:59 PM EasternExtended Trading$7.34 0.00 (0.00%) As of 05:29 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Bausch Health Companies Inc. operates as a diversified specialty pharmaceutical and medical device company in the United States and internationally. It develops, manufactures, and markets a range of products primarily in gastroenterology, hepatology, neurology, dermatology, international pharmaceuticals, over-the-counter (OTC) products, aesthetic medical devices, and eye health. The company operates through five segments: Salix, International, Solta Medical, Diversified, and Bausch + Lomb. The Salix segment provides gastroenterology products in the United States. The International segment sells aesthetic medical devices, branded pharmaceuticals, generic pharmaceuticals, and OTC products internationally. The Solta Medical segment engages in the sale of aesthetic medical devices. The Diversified segment offers pharmaceutical products in the areas of neurology and certain other therapeutic classes; generic products; ortho dermatologic; and dentistry products in the United States. The Bausch + Lomb segment offers products in the areas of vision care, surgical, and ophthalmic pharmaceuticals products. The company was formerly known as Valeant Pharmaceuticals International, Inc. and changed its name to Bausch Health Companies Inc. in July 2018. Bausch Health Companies Inc. is headquartered in Laval, Canada.NewAmsterdam Pharma NASDAQ:NAMS$27.00 +1.34 (+5.22%) Closing price 04:00 PM EasternExtended Trading$26.97 -0.03 (-0.11%) As of 05:39 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with metabolic disease. It is developing obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases. The company also develops Obicetrapib which is in Phase 2a clinical trial for Alzheimer's disease. NewAmsterdam Pharma Company N.V. is headquartered in Naarden, the Netherlands.Urogen Pharma NASDAQ:URGN$18.88 +0.08 (+0.43%) Closing price 04:00 PM EasternExtended Trading$18.92 +0.04 (+0.21%) As of 05:08 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution. The company's lead product candidate is UGN-102 for the treatment of several forms of non-muscle invasive urothelial cancer that include low-grade upper tract urothelial cancer and low-grade intermediate risk non-muscle invasive bladder cancer (NMIBC). It is also developing UGN-301 for the treatment of high-grade NMIBC. The company has license agreement with Agenus Inc. to develop, make, use, sell, import, and commercialize products of Agenus for the treatment of cancers of the urinary tract via intravesical delivery; strategic research collaboration agreement with MD Anderson focusing on the sequential use of UGN-201 and UGN-301 for the treatment of NMIBC; and licensing and supply agreement with medac Gesellschaft für klinische Spezialpräparate m.b.H. to develop UGN-103 in low-grade intermediate risk NMIBC and UGN-104 in low-grade upper tract urothelial carcinoma. UroGen Pharma Ltd. was incorporated in 2004 and is based in Princeton, New Jersey. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Why Hedge Fund Elliott Bet $4B on Pepsi and Sees Over 50% Upside Palantir Insider Selling: Risk Signal or Normal Activity? Advanced Micro Devices' 2026 Forecasts Are Way Too Low Salesforce Stumbles, But Investors Eye a Major Comeback Buy the Dip? GitLab’s Bullish Case Outweighs the Bears Affirm Crushes Earnings Expectations, Turns Bears into Believers Lockheed Martin: Is the Market Overlooking This Defensive Giant? Gold’s Explosive Rally: GDX ETF May Be the Fast Track to Profits Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
